Floatz logo

cd22 car-transduced t cells

Recurrent Lymphoblastic Lymphoma

Ohio State University Comprehensive Cancer CenterCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

83 Active assets in the Recurrent Lymphoblastic Lymphoma cohort.

Asset / SponsorPhaseRating
Cladribine
Fifth Affiliated Hospital, Sun Yat-Sen University
Phase 4BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
University of Washington
Phase 4BBB
ASPARAGINASE
Therapeutic Advances in Childhood Leukemia Consortium
Phase 4BBB
PEGASPARGASE
Chongqing Peg-Bio Biopharm Co., Ltd.
Phase 4BBB
MERCAPTOPURINE ANHYDROUS
City of Hope Medical Center
Phase 4BBB

View all 50 →

Same molecule, other indications

cd22 car-transduced t cells is also rated in:

B-cell acute lymphoblastic leukemiaDormant
BB
Indicative ·
68 / 100
View asset →
B-cell adult acute lymphocytic leukemiaDormant
BB
Indicative ·
64 / 100
View asset →
Lymphoma, B-CellDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →